Epistem Holdings Discussion Board http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion http://www.iii.co.uk/icons/logos/uk_logo.gif http://www.iii.co.uk tag:iii.co.uk,2003:tst.9498762
Daniel Stewart have increased their full year to June sales figures for 2012 and 2013 respectively from £5m to £6.2m and from £5.8 to £7.8m. These uplifts are significant in relative terms being respectively up 24% and 34%. They are also using the less guarded language of 'financially self-sufficient' and 'strong balance sheet' and firmly sticking to their BUY recommendation.

For 'Interim revenues...ahead of expectations' - in my humble opinion read - the company have filled more of the revenue void left by the end of Novartis' income stream than we expected.

For 'well positioned to accelerate the progress of it's pipeline' (of development programmes) - imho read - Genedrive is looking really good for a strong roll-out, Biomarkers are steaming ahead and garnering industry wide interest, and the Company has, off it's own back, at least partly filled the gap left by Novartis with regard to further developing identified 'leads'/novel regulatorsof epithelial tissue in regenerative medicine and oncology.

This aforementioned 'gap' is, again imho, less than one year off being fully filled by either Novartis' return (by Feb 2013 for a decision under the terms of the previous agreement) or by another 'heavyweight partner shortly after the 'decision' expiry period of that agreement with Novartis.

Personalised Medicine is where it's at, and Epistem is, and will continue to be, all over it, with increased and increasing investment in these development programmes.

The strong buy is for the long term as always. By ignateus ignoramus ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9498762&action=detail Mon, 02 Apr 2012 11:40:00 GMT ignateus ignoramus tag:iii.co.uk,2003:tst.9402024 By Hybridan | Thu, 08/03/2012 - 09:23
http://bit.ly/ztGH6H By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9402024&action=detail Thu, 08 Mar 2012 08:39:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9395426 7TH March 2012
8:40 am
http://bit.ly/wcU6Yb By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9395426&action=detail Wed, 07 Mar 2012 08:07:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9387204 Tuesday, March 06, 2012
http://bit.ly/AuUMwr By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9387204&action=detail Mon, 05 Mar 2012 21:20:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9385362 2:08 pm by Philip Whiterow
- adds broker comment
http://bit.ly/A7YVpn By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9385362&action=detail Mon, 05 Mar 2012 13:34:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9383199 7:47 am by Philip Whiterow
http://bit.ly/zZfXuH By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9383199&action=detail Mon, 05 Mar 2012 06:59:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9362626 February 28. at 4:36 pm
http://bit.ly/wxjW8M By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9362626&action=detail Tue, 28 Feb 2012 16:04:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9361332 February 28. at 1:42 pm
http://bit.ly/wPkxPS By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9361332&action=detail Tue, 28 Feb 2012 12:52:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9132261 ')" target="_new" rel="nofollow">http://www.google.com/finance?q=LON:EHP

http://www.google.com/finance?q=LON:VAL By dickie3times ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9132261&action=detail Sat, 07 Jan 2012 20:33:00 GMT dickie3times tag:iii.co.uk,2003:tst.9129099 Broker Round
January 06. at 3:29 pm
http://bit.ly/A3QfU0 By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9129099&action=detail Fri, 06 Jan 2012 14:46:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9127558 11:12 am by Ian Lyall
http://bit.ly/yRX76l By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9127558&action=detail Fri, 06 Jan 2012 10:28:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.9109688 ')" target="_new" rel="nofollow">http://www.theshedend.com/topic/19000-a-tragic-tale-of-a-harlequins-rugby-hope-jack-brennan/

Epetheloid Sarcoma..the type that Jack Brennan is suffering from, is currently being treated with 'new' experimental drugs in conjunction with chemo therapy at the Royal Marsden under the care of Prof. Ian Juddson, Britain's foremost oncologist in this sphere.
http://www.ecancermedicalscience.com/tv/most-viewed.asp?play=63&cid=0&scid=0&q=

ValiRx's GeneICE technology has been developed for silencing rebellious genes, which cause conditions such as cancer and various neurological problems. The 'sarcomas' or soft tissue cancers could also be targeted by the drugs being developed by VALiRx

Imperial College, University of London, has been working in collaboration with ValiRx and is currently carrying out the late pre-clinical development of ValiRx's lead therapeutic, VAL101 with funding awarded from the Eurostars scheme. The company announced that stability and toxicology studies are currently underway. The production of the VAL101 compound is going to plan and has been optimised and simplified, which by extension makes the compound cheaper to produce, thereby adding future value.
More on this innovative bio-pharma company....

Hybridan raises target price 3-fold to... 1.66p !
http://www.proactiveinvestors.co.uk/companies/news/37128/ValiRx%20has%20its%20price%20target%20increased%20by%20broker%20Hybridan

proactive news/articles: Everyone a 'positive' update
http://www.proactiveinvestors.co.uk/LON:VAL/ValiRx/

Video-interview-unlimited potential of GeneICE
http://www.proactiveinvestors.co.uk/companies/stocktube/760/satu-vainikka-from-valirx-talks-about-the-unlimited-potential-of-geneice-.html

By dickie3times ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9109688&action=detail Thu, 29 Dec 2011 21:13:00 GMT dickie3times tag:iii.co.uk,2003:tst.9009558 ')" target="_new" rel="nofollow">http://www.proactiveinvestors.co.uk/companies/news/36271/epistem-shares-could-be-worth-429-pence-each-says-daniel-stewart-36271.html

Epistem shares could be worth 429 pence each, says Daniel Stewart
2:47 pm by Giles GwinnettThe company will use the net proceeds to accelerate the development and commercialisation of its Genedrive molecular diagnostic device
Broker Daniel Stewart reckons shares in stem cell specialists Epistem Holdings (LON:EHP) could be worth 429 pence each (current price: 362.5 pence).

Rating the stock a 'buy', analyst Vadim Alexandre highlighted last week's announcement, in which the firm said it planned to raise £2.8 million before expenses by placing 793,398 shares at 350 pence each.

The company will use the net proceeds to accelerate the development and commercialisation of its Genedrive molecular diagnostic device.

Genedrive is a diagnostic system that can analyse markers for oncology and personalised medicine applications and is expected to provide a new cost effective approach to the rapid diagnosis of bacterial, viral, fungal and gene mutations.

Clinical trials are underway in various diagnostic sectors including pharmacogenomics, infectious disease and biodefence and successful clinical studies were recently completed in India for tuberculosis.

The device recorded maiden sales revenue in full year 2011 and the company is expecting to see rapid revenue growth of the device and assays next year, said Alexandre in a note.

Epistem focuses its research on adult stem cells that are located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, the breast and the prostate gland. It operates three distinct business divisions: contract research services, biomarkers and novel therapies. By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=9009558&action=detail Tue, 29 Nov 2011 14:25:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8997016 25/11/2011 Ben Jaglom
http://www.growthcompany.co.uk/news/1675648/epistem-to-raise-28-million.thtml

Biotech concern Epistem Holdings (EHP) has raised £2.8 million through a placing at 350p a share.

The AIM-quoted biotech - which raised the amount at a discount of 3.4 per cent to the previous day's closing price- noted it is to use the proceeds to 'accelerate the development and commercialisation of its handheld diagnostics 'Genedrive' device. The company enthused it expects Genedrive to provide a 'significant technological advance and new cost effective approach to the rapid diagnosis of bacterial, viral, fungal and gene mutations.'

Last recommended by Growth Company Investor in 2009 at 372.5p the shares currently trade at 362.5p, valuing the business at £28.8 million. A company that has made impressive gains of late, having almost doubled in valued since a 2009 value of 190p the latest placing should bolster its plans for Genedrive. Currently trading at 362.5p the shares look fairly priced. Hold.




Tags: Biotech on AIM, Handheld devicves, Heavyweights on AIM, Pharma, Placing

Sector: Pharmaceuticals & Biotechnology

Companies: EpiStem By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=8997016&action=detail Fri, 25 Nov 2011 15:31:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8974918 http://www.iii.co.uk/investment/detail?code=cotn:EHP.L&display=discussion&id=8974918&action=detail Mon, 21 Nov 2011 10:23:00 GMT ignateus ignoramus